Dr. Michael Miedema Recognized by Harvard T.H. Chan School of Public Health with 2023 Emerging Public Health Professional Award

Sep 25, 2023
Image
Dr. Miedema

The Harvard T.H. Chan School of Public Health announced that Michael Miedema, MD, MPH, is the recipient of the prestigious 2023 Emerging Public Health Professional Award. The award recognizes early-career public health achievements and contributions of Harvard Chan School graduates who received their degree within the past 10 years. This award is one of four 2023 Alumni Awards granted to leading alumni chosen by their peers through a nomination and voting process.

Dr. Miedema is a cardiologist, researcher and director of the Nolan Family Center for Cardiovascular Health at the Minneapolis Heart Institute Foundation® (MHIF) where he focuses his research on determining the optimal individual and population-based approaches for the prevention of cardiovascular disease. He maintains an active clinical practice as director of cardiovascular prevention at Allina Health Minneapolis Heart Institute® where he focuses on cardiovascular prevention, seeing over a thousand patients each year. In 2022, he was named the team cardiologist for the Minnesota Timberwolves.

Dr. Miedema obtained his medical degree and completed a cardiovascular fellowship at the University of Minnesota Medical School and a master’s degree in public health from the Harvard T.H. Chan School of Public Health.

The Harvard Chan School announced the recipients of the awards will present the awards during their alumni weekend events September 28-30. See the Harvard Chan School announcement, including Dr. Miedema’s selection for the 2023 Emerging Public Health Professional Award.

Give the Gift of Hope
4 photos of families smiling

The Minneapolis Heart Institute Foundation® (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, we are dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

Thanks to the generosity of donors like you, we can continue this life-saving work. Please make a gift to support the area of greatest need.

Research Milestone: FDA approves device used as alternative to open-heart

blue background
Triclip team

We are honored to celebrate the culmination of years of research that has resulted in new technologies for patients! In the few last weeks, we announced a similar research milestone with the FDA approval of the TriClip system for tricuspid regurgitation. We celebrated this important milestone with local media KSTP-TV, who spotlighted the importance of this new technology. We were proud to be a leading clinical site led by Global PI Dr. Paul Sorajja and the MHIF research team who contributed significant data to the pivotal trial.